Literature DB >> 11458330

Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent.

V M Rao1, J L Haslam, V J Stella.   

Abstract

Sustained-release formulations such as hydroxypropyl methylcellulose (HPMC)-based hydrophilic matrix tablets of poorly water-soluble drugs often result in incomplete release because of the poor solubility and dissolution rate of the drug in the hydrophilic matrix. Sulfobutylether-beta-cyclodextrins ((SBE)(7M)-beta-CDs) have been known to improve the solubility of such drugs by forming inclusion complexes. The present paper deals with the modification of drug release from an HPMC-based matrix tablet of a sparingly water-soluble drug, prednisolone (PDL), using (SBE)(7M)-beta-CD as a solubilizing agent. Tablets were prepared by direct compression of a physically mixed PDL, (SBE)(7M)-beta-CD, and polymer. On exposure to water, an in situ PDL:(SBE)(7M)-beta-CD complex was formed in the gel layer, and enhanced drug release relative to a control formulation was observed (lactose used as the excipient instead of (SBE)(7M)-beta-CD ). Other possible changes due to the incorporation of (SBE)(7M)-beta-CD in the formulation were also probed. Incorporation of (SBE)(7M)-beta-CD lead to a higher water uptake relative to the control (lactose) formulation. For a fixed total tablet weight, polymer type, and loading, the drug release rate appeared to depend on the molar ratio of (SBE)(7M)-beta-CD to PDL and not the absolute amount of (SBE)(7M)-beta-CD present in the matrix tablet. This work shows that incorporation of (SBE)(7M)-beta-CD into the matrix tablets could be considered in designing a sustained-release tablet of poorly water-soluble drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458330     DOI: 10.1002/jps.1034

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.

Authors:  Paulo José Salústio; Patrícia Pontes; Claúdia Conduto; Inês Sanches; Catarina Carvalho; João Arrais; Helena M Cabral Marques
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

2.  Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.

Authors:  Ville Vartiainen; Luis M Bimbo; Jouni Hirvonen; Esko I Kauppinen; Janne Raula
Journal:  Pharm Res       Date:  2016-09-07       Impact factor: 4.200

Review 3.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

4.  Effect of auxiliary substances on complexation efficiency and intrinsic dissolution rate of gemfibrozil-beta-CD complexes.

Authors:  Fareen Sami; Betty Philip; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2009-12-15       Impact factor: 3.246

5.  Solid Dispersion Matrix Tablet Comprising Indomethacin-PEG-HPMC Fabricated with Fusion and Mold Technique.

Authors:  A Mesnukul; K Yodkhum; T Phaechamud
Journal:  Indian J Pharm Sci       Date:  2009-07       Impact factor: 0.975

6.  Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogel.

Authors:  Tianyuan Ci; Liang Chen; Lin Yu; Jiandong Ding
Journal:  Sci Rep       Date:  2014-07-01       Impact factor: 4.379

7.  Formation and Physico-Chemical Evaluation of Nifedipine-hydroxypropyl-β-cyclodextrin and Nifedipine-methyl-β-cyclodextrin: The Development of Orodispersible Tablets.

Authors:  Emma Adriana Ozon; Marian Novac; Daniela Gheorghe; Adina Magdalena Musuc; Mirela Adriana Mitu; Iulian Sarbu; Valentina Anuta; Adriana Rusu; Simona Petrescu; Irina Atkinson; Dumitru Lupuliasa
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-12

8.  Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma.

Authors:  Yi-Dan Chen; Zhong-Yuan Liang; Yan-Yan Cen; He Zhang; Mei-Gui Han; Yun-Qiao Tian; Jie Zhang; Shu-Jun Li; Da-Sheng Yang
Journal:  Drug Des Devel Ther       Date:  2015-11-20       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.